source
- Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’Boehringer Ingelheim has suspended a phase 1 trial of an investigational small molecule drug while it seeks to understand a “safety event,” although the German pharma isn't shedding light on the na…Fierce Biotech · 19h ago↗ source
- FDA approves Regeneron’s garetosmab for ultra-rare bone-forming diseaseThe FDA has granted approval to Regeneron's antibody garetosmab, which targets activin A, for the treatment of fibrodysplasia ossificans progressiva (FOP). FOP is an ultra‑rare disorder that causes…